ASX Announcements
The company’s latest announcements on the ASX
| Document name | date | Link |
|---|---|---|
| TrivarX Requests Pre-Submission Meeting with US FDA | 24 Sep 2024 8:23am | View ASX Announcement |
| Appendix 4G | 19 Sep 2024 8:27am | View ASX Announcement |
| Corporate Governance Statement | 19 Sep 2024 8:27am | View ASX Announcement |
| 2024 Annual Report | 19 Sep 2024 8:27am | View ASX Announcement |
| Notification under Listing Rule 4.3D | 19 Sep 2024 8:22am | View ASX Announcement |
| Appendix 4E – Preliminary Final Report | 29 Aug 2024 9:08am | View ASX Announcement |
| Notification of cessation of securities – TRI | 20 Aug 2024 9:16am | View ASX Announcement |
| June 2024 Quarterly Activities Report and Appendix 4C | 31 Jul 2024 1:49pm | View ASX Announcement |
| Initial Director’s Interest Notice – Tony Keating | 30 Jul 2024 9:27am | View ASX Announcement |
| Final Director’s Interest Notice – Tom Young | 30 Jul 2024 9:26am | View ASX Announcement |
| TechKnow Invest Roadshow presentation and livestream links | 30 Jul 2024 9:22am | View ASX Announcement |
| Positive Results from Phase 2 SAMDE Study | 30 Jul 2024 9:07am | View ASX Announcement |
| Trading Halt | 29 Jul 2024 8:46am | View ASX Announcement |
| Appointment of Dr Tony Keating & Resignation of Dr Tom Young | 29 Jul 2024 2:22pm | View ASX Announcement |
| Change in substantial holding | 12 Jul 2024 2:22pm | View ASX Announcement |
| Change of Director’s Interest Notice – David Trimboli | 10 Jul 2024 8:00am | View ASX Announcement |
| Change of Director’s Interest Notice – Chris Ntoumenopoulos | 10 Jul 2024 8:00am | View ASX Announcement |
| Cleansing Notice | 10 Jul 2024 7:55am | View ASX Announcement |
| Application for quotation of securities – TRI | 10 Jul 2024 7:49am | View ASX Announcement |
| Application for quotation of securities – TRI | 10 Jul 2024 7:45am | View ASX Announcement |
| Notification regarding unquoted securities – TRI | 10 Jul 2024 7:45am | View ASX Announcement |
| Notification regarding unquoted securities – TRI | 10 Jul 2024 7:40am | View ASX Announcement |
| Application for quotation of securities – TRI | 10 Jul 2024 7:27am | View ASX Announcement |
| Completion of Phase 2 SAMDE Trial | 10 Jul 2024 6:25am | View ASX Announcement |
| Proposed issue of securities – TRI | 9 Jul 2024 12:34pm | View ASX Announcement |
| Results of General Meeting | 5 Jul 2024 9:24am | View ASX Announcement |
| TrivarX SAMDE Trial Update | 20 Jun 2024 6:24am | View ASX Announcement |
| Update – Proposed issue of securities – TRI | 11 Jun 2024 7:10am | View ASX Announcement |
| Proposed issue of securities – TRI | 4 Jun 2024 8:48am | View ASX Announcement |
| Letter to Shareholders & Notice of GM & Proxy Form | 4 Jun 2024 8:33am | View ASX Announcement |
| Presentation – Investor Webinar | 22 May 2024 7:57am | View ASX Announcement |
| Investor Webinar | 22 May 2024 7:54am | View ASX Announcement |
| Notification regarding unquoted securities – TRI | 16 May 2024 7:51am | View ASX Announcement |
| Change in substantial holding | 14 May 2024 10:15am | View ASX Announcement |
| Cleansing Notice | 10 May 2024 8:03am | View ASX Announcement |
| Application for quotation of securities – TRI | 10 May 2024 8:01am | View ASX Announcement |
| Notification regarding unquoted securities – TRI | 10 May 2024 7:55am | View ASX Announcement |
| Application for quotation of securities – TRI | 10 May 2024 7:49am | View ASX Announcement |
| Application for quotation of securities – TRI | 10 May 2024 7:46am | View ASX Announcement |
| Proposed issue of securities – TRI | 10 May 2024 6:21am | View ASX Announcement |
| Proposed issue of securities – TRI | 2 May 2024 6:50am | View ASX Announcement |
| Proposed issue of securities – TRI | 2 May 2024 6:49am | View ASX Announcement |
| TrivarX Receives Firm Commitments to Raise $2.5 million | 2 May 2024 6:49am | View ASX Announcement |
| Trading Halt | 30 Apr 20246:48am | View ASX Announcement |
| March 2024 Quarterly Activities Report and Appendix 4C | 29 Apr 2024 2:56pm | View ASX Announcement |
| Cleansing Notice | 26 Mar 2024 5:46am | View ASX Announcement |
| Application for quotation of securities – TRI | 26 Mar 2024 5:44am | View ASX Announcement |
| Cleansing Notice | 1 Mar 2024 7:06am | View ASX Announcement |
| Application for quotation of securities – TRI | 1 Mar 2024 7:04am | View ASX Announcement |
| Appendix 4D & Half-Year Financial Report to 31 December 2023 | 28 Feb 2024 3:06pm | View ASX Announcement |
| Positive Engagement Meeting with US FDA for MEB-001 | 28 Feb 2024 :38am | View ASX Announcement |
| Response to ASX Price Query | 22 Feb 2024 10:08am | View ASX Announcement |
| Cleansing Notice | 15 Feb 2024 5:22am | View ASX Announcement |
| Application for quotation of securities – TRI | 15 Feb 2024 5:20am | View ASX Announcement |
| Research Collaboration with Northern Michigan University | 9 Feb 2024 5:22am | View ASX Announcement |
| TrivarX Receives $888k R&D Tax Incentive | 8 Feb 2024 5:37am | View ASX Announcement |
| TRI-001 Algorithm and Phase 2 Trial Update | 5 Feb 2024 5:27am | View ASX Announcement |
| December 2023 Quarterly Activities Report and Appendix 4C | 31 Jan 2024 8:42am | View ASX Announcement |
| Notification of cessation of securities – TRI opens new window | 31 Jan 2024 8:42am | View ASX Announcement |
| Document name | date | Link |
|---|---|---|
| Notification of cessation of securities – TRI | 21 Dec 2023 7:51am | View ASX Announcement |
| Cleansing Notice | 19 Dec 2023 5:18am | View ASX Announcement |
| Application for quotation of securities – TRI | 19 Dec 2023 5:18am | View ASX Announcement |
| Proposed issue of securities – TRI | 18 Dec 2023 6:36am | View ASX Announcement |
| Change of Share Registry Details | 12 Dec 2023 10:43am | View ASX Announcement |
| Results of Annual General Meeting | 29 Nov 2023 9:16am | View ASX Announcement |
| Cleansing Notice | 20 Nov 2023 6:10am | View ASX Announcement |
| Application for quotation of securities – TRI | 20 Nov 2023 6:07am | View ASX Announcement |
| Phase 2 SAMDE Study Update | 20 Nov 2023 5:36am | View ASX Announcement |
| Proposed issue of securities – TRI | 16 Nov 2023 10:26am | View ASX Announcement |
| Investor Presentation – November 2023 | 16 Nov 2023 6:07am | View ASX Announcement |
| Cleansing Notice | 15 Nov 2023 6:04am | View ASX Announcement |
| Application for quotation of securities – TRI | 15 Nov 2023 5:55am | View ASX Announcement |
| Option Terms and Conditions | 14 Nov 2023 7:54am | View ASX Announcement |
| Proposed issue of securities – TRI | 14 Nov 2023 7:44am | View ASX Announcement |
| Proposed issue of securities – TRI | 14 Nov 2023 7:40am | View ASX Announcement |
| Letter to Shareholders & Notice of AGM & Proxy Form | October 2023 | View ASX Announcement |
| September 2023 Quarterly Activities Report and Appendix 4C | October 2023 | View ASX Announcement |
| Completion of Consolidation Capital | October 2023 | View ASX Announcement |
| Consolidation/Split – TRI | October 2023 | View ASX Announcement |
| Change in substantial holding | October 2023 | View ASX Announcement |
| Change of Director’s Interest Notice – David Trimboli | October 2023 | View ASX Announcement |
| Change of Director’s Interest Notice – Chris Ntoumenopolos | October 2023 | View ASX Announcement |
| Notification regarding unquoted securities – MEB | October 2023 | View ASX Announcement |
| Cleansing Notice | October 2023 | View ASX Announcement |
| Results of General Meeting | October 2023 | View ASX Announcement |
| Board and Management Transition | October 2023 | View ASX Announcement |
| Application for quotation of securities – MEB | October 2023 | View ASX Announcement |
| Change of Company Name ASX Code | October 2023 | View ASX Announcement |
| Notification of cessation of securities – MEB | October 2023 | View ASX Announcement |
| Notice of AGM and Closing Date for Director Nominations | October 2023 | View ASX Announcement |
| Appendix 4G | September 2023 | View ASX Announcement |
| Corporate Governance Statement | September 2023 | View ASX Announcement |
| 2023 Annual Report | September 2023 | View ASX Announcement |
| Proposed issue of securities – MEB | September 2023 | View ASX Announcement |
| Letter to Shareholders & Notice of GM & Proxy Form | September 2023 | View ASX Announcement |
| Phase 2 Trial Commences for SAMDE Study | September 2023 | View ASX Announcement |
| Appendix 4E – Preliminary Final Report | August 2023 | View ASX Announcement |
| Notification of cessation of securities – MEB | August 2023 | View ASX Announcement |
| Change in substantial holding | August 2023 | View ASX Announcement |
| Cleansing Notice | August 2023 | View ASX Announcement |
| Application for quotation of securities – MEB | August 2023 | View ASX Announcement |
| Proposed issue of securities – MEB | August 2023 | View ASX Announcement |
| Medibio Receives Firm Commitments to Raise $2.25m | August 2023 | View ASX Announcement |
| Trading Halt | August 2023 | View ASX Announcement |
| June 2023 Quarterly Activities Report and Appendix 4C | July 2023 | View ASX Announcement |
| Phase 1 Trial Completed for SAMDE Study | July 2023 | View ASX Announcement |
| Update on Breakthrough Device Designation with US FDA | July 2023 | View ASX Announcement |
| Notification regarding unquoted securities – MEB | July 2023 | View ASX Announcement |
| Notification regarding unquoted securities – MEB | July 2023 | View ASX Announcement |
| Notification regarding unquoted securities – MEB | July 2023 | View ASX Announcement |
| Application for quotation of securities – MEB | July 2023 | View ASX Announcement |
| Change of Director’s Interest Notice – David Trimboli | June 2023 | View ASX Announcement |
| Change of Director’s Interest Notice – Chris Ntoumenopoulos | June 2023 | View ASX Announcement |
| Notification regarding unquoted securities – MEB | June 2023 | View ASX Announcement |
| Application for quotation of securities – MEB | June 2023 | View ASX Announcement |
| Notification of cessation of securities – MEB | June 2023 | View ASX Announcement |
| Notification regarding unquoted securities – MEB | May 2023 | View ASX Announcement |
| Application for quotation of securities – MEB | May 2023 | View ASX Announcement |
| Medibio Completes Share Purchase Plan | May 2023 | View ASX Announcement |
| Results of Extraordinary General Meeting | May 2023 | View ASX Announcement |
| Investor Presentation – May 2023 | May 2023 | View ASX Announcement |
| Change in Venue and Time for Extraordinary General Meeting | May 2023 | View ASX Announcement |
| March 2023 Quarterly Activities Report and Appendix 4C | April 2023 | View ASX Announcement |
| Letter to Shareholders & Notice of EGM & Proxy Form | April 2023 | View ASX Announcement |
| MEB Executes Bridging Loans with Directors | April 2023 | View ASX Announcement |
| Initial Director’s Interest Notice – Thomas Young | April 2023 | View ASX Announcement |
| Share Purchase Plan Supplementary Prospectus | April 2023 | View ASX Announcement |
| Final Director’s Interest Notice | April 2023 | View ASX Announcement |
| Board & Managment Changes & Change of Offices | April 2023 | View ASX Announcement |
| Update on Share Purchase Plan Timetable | April 2023 | View ASX Announcement |
| Appendix 3Z | March 2023 | View ASX Announcement |
| Resignation of Non-Executive Director | March 2023 | View ASX Announcement |
| Share Purchase Plan Prospectus | March 2023 | View ASX Announcement |
| Medibio Lodges Breakthrough Device Designation with FDA | February 2023 | View ASX Announcement |
| Update to Share Purchase Plan Timetable | February 2023 | View ASX Announcement |
| Half Yearly Report and Accounts | February 2023 | View ASX Announcement |
| Change in substantial holding | February 2023 | View ASX Announcement |
| 708A Cleansing Notice | February 2023 | View ASX Announcement |
| Application for quotation of securities – MEB | February 2023 | View ASX Announcement |
| Update to Share Purchase Plan Timetable | February 2023 | View ASX Announcement |
| Appendix 3X | February 2023 | View ASX Announcement |
| Proposed issue of securities – MEB | February 2023 | View ASX Announcement |
| MEB to Raise up to $2.75 million By Way of a Placement & SPP | February 2023 | View ASX Announcement |
| Medibio Appoints Non-Executive Director to the Board | February 2023 | View ASX Announcement |
| Trading Halt | February 2023 | View ASX Announcement |
| Medibio Quarterly Update and Cashflow Report | February 2023 | View ASX Announcement |
| Notification of cessation of securities – MEB | February 2023 | View ASX Announcement |
| Appendix 3Z | February 2023 | View ASX Announcement |
| Document name | date | Link |
|---|---|---|
| Medibio Receives R&D Tax Incentive Refund | November 2022 | View ASX Announcement |
| Results of Annual General Meeting | November 2022 | View ASX Announcement |
| CEO Presentation to 2022 AGM | November 2022 | View ASX Announcement |
| Chair’s Address to the 2022 Annual General Meeting | November 2022 | View ASX Announcement |
| Resignation of Director and Resolution Withdrawal | November 2022 | View ASX Announcement |
| Medibio Quarterly Update and Cashflow Report | October 2022 | View ASX Announcement |
| Medibio Announces Appointment of Non-Executive Chair | October 2022 | View ASX Announcement |
| Notice of Annual General Meeting/Proxy Form | October 2022 | View ASX Announcement |
| Appendix 4G and Corporate Governance Statement | September 2022 | View ASX Announcement |
| 2022 Annual Report | September 2022 | View ASX Announcement |
| Director Nomination Closing Date for AGM | September 2022 | View ASX Announcement |
| Medibio Appoints CEO | September 2022 | View ASX Announcement |
| Initial Directors Interest Notice | September 2022 | View ASX Announcement |
| Appendix 4E and Preliminary Final Report | August 2022 | View ASX Announcement |
| 708A Cleansing Notice | August 2022 | View ASX Announcement |
| Notification regarding unquoted securities – MEB | August 2022 | View ASX Announcement |
| Notification regarding unquoted securities – MEB | August 2022 | View ASX Announcement |
| Non-Executive Director Appointment | August 2022 | View ASX Announcement |
| Results of General Meeting | July 2022 | View ASX Announcement |
| Medibio Quarterly Update and Cashflow Report | July 2022 | View ASX Announcement |
| Sleep Analysis Depressive Burden Study Clinical Trial | July 2022 | View ASX Announcement |
| Update – Proposed issue of securities – MEB | July 2022 | View ASX Announcement |
| Notice of Extraordinary General Meeting/Proxy Form | July 2022 | View ASX Announcement |
| Notification of cessation of securities – MEB | July 2022 | View ASX Announcement |
| Notification of cessation of securities – MEB | July 2022 | View ASX Announcement |
| Change in substantial holding | July 2022 | View ASX Announcement |
| 708A Cleansing Notice | June 2022 | View ASX Announcement |
| Application for quotation of securities – MEB | June 2022 | View ASX Announcement |
| Appendix 3Z | June 2022 | View ASX Announcement |
| Proposed issue of securities – MEB | June 2022 | View ASX Announcement |
| MEB to Raise $1.4m by way of a Placement & MD/CEO Resigns | June 2022 | View ASX Announcement |
| Reinstatement to Quotation | June 2022 | View ASX Announcement |
| Update on Voluntary Suspension | June 2022 | View ASX Announcement |
| Voluntary Suspension | June 2022 | View ASX Announcement |
| Appendix 3Z | June 2022 | View ASX Announcement |
| FDA Confirm Diagnostic Method on Depression Validation Trial | June 2022 | View ASX Announcement |
| 708A Cleansing Notice | June 2022 | View ASX Announcement |
| Application for quotation of securities – MEB | June 2022 | View ASX Announcement |
| Trading Halt | May 2022 | View ASX Announcement |
| Non-Executive Director Moves to Advisory Board | May 2022 | View ASX Announcement |
| Medibio Quarterly Update and Cashflow Report | April 2022 | View ASX Announcement |
| Medibio to Host Live Corporate Webinar on March 25 | March 2022 | View ASX Announcement |
| Application for quotation of securities – MEB | March 2022 | View ASX Announcement |
| Change in substantial holding | March 2022 | View ASX Announcement |
| Initial Director’s Interest Notice | March 2022 | View ASX Announcement |
| Entitlement Offer Shareholder Withdrawal Rights | March 2022 | View ASX Announcement |
| Investor Presentation March 2022 | March 2022 | View ASX Announcement |
| Non-Executive Director Appointment | March 2022 | View ASX Announcement |
| Termination of Underwriting Agreement | March 2022 | View ASX Announcement |
| Half Yearly Report and Accounts | February 2022 | View ASX Announcement |
| Application for quotation of securities – MEB | February 2022 | View ASX Announcement |
| 708A Cleansing Notice | February 2022 | View ASX Announcement |
| Appendix 3X | February 2022 | View ASX Announcement |
| Non-Executive Director Appointment | February 2022 | View ASX Announcement |
| Update – Proposed issue of securities – MEB | February 2022 | View ASX Announcement |
| MEB Announces Extension to Entitlement Offer | February 2022 | View ASX Announcement |
| Results of Extraordinary General Meeting | February 2022 | View ASX Announcement |
| Medibio Quarterly Update and Cashflow Report | January 2022 | View ASX Announcement |
| Despatch of Offer Letter to Eligible Shareholders | January 2022 | View ASX Announcement |
| Letter to Ineligible Shareholders – Entitlement Offer | January 2022 | View ASX Announcement |
| Letter to Option holders – Entitlement Offer | January 2022 | View ASX Announcement |
| Update – Proposed issue of securities – MEB | January 2022 | View ASX Announcement |
| Entitlement Offer Document | January 2022 | View ASX Announcement |
| Section 708AA(2)(F) Cleansing Notice – Entitlement Offer | January 2022 | View ASX Announcement |
| Non-Renounceable Entitlement Offer Underwriting Update | January 2022 | View ASX Announcement |
| Notification regarding unquoted securities – MEB | January 2022 | View ASX Announcement |
| Update – Proposed issue of securities – MEB | January 2022 | View ASX Announcement |
| Notification of cessation of securities – MEB | January 2022 | View ASX Announcement |
| Update to Entitlement Offer Timetable | January 2022 | View ASX Announcement |
| Document name | date | Link |
|---|---|---|
| Notice of Extraordinary General Meeting/Proxy Form | December 2021 | View ASX Announcement |
| Section 708A Cleansing Notice | December 2021 | View ASX Announcement |
| Application for quotation of securities – MEB | December 2021 | View ASX Announcement |
| Section 708A Cleansing Notice | December 2021 | View ASX Announcement |
| MEB to Raise up to $5.7 million by way of a Placement & NREO | December 2021 | View ASX Announcement |
| Proposed issue of securities – MEB | December 2021 | View ASX Announcement |
| Investor Presentation December 2021 | December 2021 | View ASX Announcement |
| Trading Halt | December 2021 | View ASX Announcement |
| Appendix 3Y | December 2021 | View ASX Announcement |
| Application for quotation of securities – MEB | December 2021 | View ASX Announcement |
| Results of Annual General Meeting | November 2021 | View ASX Announcement |
| Chairman’s Address to the 2021 Annual General Meeting | November 2021 | View ASX Announcement |
| JobKeeper Payments Notice | November 2021 | View ASX Announcement |
| Medibio Quarterly Update and Cashflow Report | October 2021 | View ASX Announcement |
| Medibio Quarterly Update and Cashflow Report | October 2021 | View ASX Announcement |
| Expiry of MEBOB Quoted Options | October 2021 | View ASX Announcement |
| Proposed issue of securities | October 2021 | View ASX Announcement |
| Notice of Annual General Meeting / Proxy Form | October 2021 | View ASX Announcement |
| LUCA Launches Today | October 2021 | View ASX Announcement |
| FDA Strategy and Regulatory Update | September 2021 | View ASX Announcement |
| Appointment of Dr Elizabeth Lombardo to Advisory Board | September 2021 | View ASX Announcement |
| CEO/MD Remuneration Update and Company Secretary Resignation | September 2021 | View ASX Announcement |
| Appendix 4G and Corporate Governance Statement | August 2021 | View ASX Announcement |
| Appendix 4E and Annual Report | August 2021 | View ASX Announcement |
| Medibio Quarterly Update and Cashflow Report | June 2021 | View ASX Announcement |
| MEB Appoints R&CPMK as Communications Agency in the US | June 2021 | View ASX Announcement |
| Newsletter to Shareholders | June 2021 | View ASX Announcement |
| Section 708A Cleansing Notice and Appendix 2A | June 2021 | View ASX Announcement |
| Medibio strengthens its IP protection | May 2021 | View ASX Announcement |
| Medibio Quarterly Update and Cashflow Report | May 2021 | View ASX Announcement |
| Re-submission of FDA 510(k) application | April 2021 | View ASX Announcement |
| Consumer Mental Health App Development – Second Test Phase | April 2021 | View ASX Announcement |
| Appendix 3G | April 2021 | View ASX Announcement |
| Section 708A Cleansing Notice and Appendix 2A | April 2021 | View ASX Announcement |
| Appendix 2A | April 2021 | View ASX Announcement |
| Proposed issue of Securities – MEB (Revised) | April 2021 | View ASX Announcement |
| MEB Share Purchase Plan Closes Strongly Oversubscribed | April 2021 | View ASX Announcement |
| Supplementary Prospectus | April 2021 | View ASX Announcement |
| Results of General Meeting | March 2021 | View ASX Announcement |
| Annual General Meeting | March 2021 | View ASX Announcement |
| Medibio Begins Implementation of ilumen in the United Kingdom | March 2021 | View ASX Announcement |
| Medibio To Present at World Forum for Sleep Medicine | March 2021 | View ASX Announcement |
| Share Purchase Plan Prospectus | March 2021 | View ASX Announcement |
| Half Yearly Report and Accounts | February 2021 | View ASX Announcement |
| Notice of General Meeting/Proxy Form | February 2021 | View ASX Announcement |
| Notice of Change of Interests of Substantial Holder | February 2021 | View ASX Announcement |
| Appendix 3G Notification of issue, conversion or payment of Equity + Securities | February 2021 | View ASX Announcement |
| Section 708A Cleansing Notice Appendix 2A | February 2021 | View ASX Announcement |
| Appendix 3G | February 2021 | View ASX Announcement |
| Appendix 3B Proposed issue of + securities | February 2021 | View ASX Announcement |
| Underwritten Share Purchase Plan Update | February 2021 | View ASX Announcement |
| Investors Presentation FEB 2021 | February 2021 | View ASX Announcement |
| Appendix 3B Proposed issue of +securities | February 2021 | View ASX Announcement |
| Proposed issue of securities – Announcement Summary 2 | February 2021 | View ASX Announcement |
| Medibio to Raise up to $3.5 million By Way of a Placement and SPP | February 2021 | View ASX Announcement |
| Proposed issue of securities – Announcement Summary | February 2021 | View ASX Announcement |
| ASX- MEB Trading Halt | February 2021 | View ASX Announcement |
| December 2020 Quarterly Activities Report and Appendix 4C | February 2021 | View ASX Announcement |
| Medibio Granted CE Mark Approval for MEBsleep | January 2021 | View ASX Announcement |
| US FDA advises further data needed for MEBsleep approval | January 2021 | View ASX Announcement |
| Medibio’s Patent-Protected Consumer Mental Health App, Commences Initial Testing Phase | January 2021 | View ASX Announcement |
| Document name | date | Link |
|---|---|---|
| Updated Capital Structure | December 2020 | View ASX Announcement |
| Appendix 3Y Change of Director’s Interest Notice | December 2020 | View ASX Announcement |
| Appendix 3G Notification of issue, conversion or payment up of equity + securities | December 2020 | View ASX Announcement |
| Release of Securities from Escrow | December 2020 | View ASX Announcement |
| Medibio signs Global Master License and Services Agreement with Compass Group Plc. for ilumen | December 2020 | View ASX Announcement |
| Medibio Investor Webinar Presentation | December 2020 | View ASX Announcement |
| Update on Breakthrough Device Program | December 2020 | View ASX Announcement |
| Results of Annual General Meeting | November 2020 | View ASX Announcement |
| Medibio Investor Webinar Presentation | November 2020 | View ASX Announcement |
| Chairman’s Address Annual General Meeting | November 2020 | View ASX Announcement |
| Amended Constitution | November 2020 | View ASX Announcement |
| MEB AGM Presentation | November 2020 | View ASX Announcement |
| Chairman’s Address Annual General Meeting | November 2020 | View ASX Announcement |
| Medibio Investor Webinar Presentation | November 2020 | View ASX Announcement |
| Chairman’s Address Annual General Meeting | November 2020 | View ASX Announcement |
| Amended Constitution | November 2020 | View ASX Announcement |
| MEB AGM Presentation | November 2020 | View ASX Announcement |
| Notice of Annual General Meeting | November 2020 | View ASX Announcement |
| Medibio Signs Clinical Trial Agreement With US-based MedBridge Healthcare LLC For its Depressive Burden Trial | October 2020 | View ASX Announcement |
| Medibio Submits Request For FDA Breakthrough Device Designation | October 2020 | View ASX Announcement |
| Appendix 3G | October 2020 | View ASX Announcement |
| Securities Trading Policy | October 2020 | View ASX Announcement |
| Updated Capital Structure | October 2020 | View ASX Announcement |
| September 2020 Quarterly Activities Report and Appendix 4C | October 2020 | View ASX Announcement |
| Notice of Annual General Meeting Proxy Form | October 2020 | View ASX Announcement |
| Securities Trading Policy | October 2020 | View ASX Announcement |
| Updated Capital Structure | October 2020 | View ASX Announcement |
| September 2020 Quarterly Activities Report and Appendix 4C | October 2020 | View ASX Announcement |
| Medibio Limited – Annual Report – 30 June 2020 | September 2020 | View ASX Announcement |
| Appendix 4G and Corporate Governance Statement | September 2020 | View ASX Announcement |
| FDA Strategy and Regulatory Update | August 2020 | View ASX Announcement |
| Medibio granted US Patent for Monitoring Stress Conditions Using Heartrate | August 2020 | View ASX Announcement |
| Appendix 2A Application for quotation of & securities | August 2020 | View ASX Announcement |
| Appendix 4E Preliminary Final Report 30 June 2020 | August 2020 | View ASX Announcement |
| FDA Strategy & Regulatory Update | August 2020 | View ASX Announcement |
| Medibio Announces Entitlement Issue Results | July 2020 | View ASX Announcement |
| Appendix 2A Application for quotation of + securities | July 2020 | View ASX Announcement |
| Appendix 3Y Change of Director’s Interest Notice | July 2020 | View ASX Announcement |
| June Quarterly Activities Report and Appendix 4C | July 2020 | View ASX Announcement |
| Appendix 2A Application for quotation of +securities | June 2020 | View ASX Announcement |
| Appendix 3G Notification of issue, conversion or payment up of equity +securities | June 2020 | View ASX Announcement |
| MEB Raises $2m via Placement and Fully Underwritten Entitlement Offer | June 2020 | View ASX Announcement |
| Offer Document Entitlement Issue | June 2020 | View ASX Announcement |
| Non-Renounceable Entitlement Offer Cleansing Notice under Section 708AA(2)(F) of the Corporations Act 2001 (Cth) | June 2020 | View ASX Announcement |
| Section 708A Cleansing Notice | June 2020 | View ASX Announcement |
| Investor Presentation | June 2020 | View ASX Announcement |
| Notification to ineligible shareholders of Entitlement Offer | June 2020 | View ASX Announcement |
| Notification of pro-rata non-renounceable Entitlement Issue | June 2020 | View ASX Announcement |
| Notification to eligible shareholders of Entitlement Offer | June 2020 | View ASX Announcement |
| Section 708A Cleansing Notice and Appendix 2A | June 2020 | View ASX Announcement |
| Despatch of Offer Letter to Eligible Shareholders | June 2020 | View ASX Announcement |
| Appendix 3G Notification of issue, conversion or payment up of equity +securities | June 2020 | View ASX Announcement |
| MEB Announces Extension to Entitlement Offer | June 2020 | View ASX Announcement |
| Medibio Settles Joint Venture Dispute | June 2020 | View ASX Announcement Announcement Summary |
| Medibio’s ilumen™ supporting the global workforce during COVID-19 health crisis | April 2020 | View ASX Announcement |
| Final Compass Pilot completed successfully | April 2020 | View ASX Announcement |
| Capital Structure Update | April 2020 | View ASX Announcement |
| Medibio Submits FDA 510K Application to the FDA for its Sleep Staging Medical Software Device | April 2020 | View ASX Announcement |
| Quarterly Activities Report and Appendix 4C | April 2020 | View ASX Announcement |
| Executive Appointments at Medibio to Support Growth of ilumen™ | March 2020 | View ASX Announcement |
| FDA Strategy Update | March 2020 | View ASX Announcement |
| Medibio Signs Memorandum of Understanding with DXC for ilumen™ | March 2020 | View ASX Announcement |
| Strategic Plan for FDA and CE Mark Approval | February 2020 | View ASX Announcement |
| Medibio Signs Annual Services Agreement with Stantec Australia for ilumen™ | February 2020 | View ASX Announcement |
| Appendix 4D and Half-Yearly Report for 31 December 2019 | February 2020 | View ASX Announcement |
| Changes to the Board | January 2020 | View ASX Announcement |
| Final Director’s Interest Notice | January 2020 | View ASX Announcement |
| Letter from the Managing Director | January 2020 | View ASX Announcement |
| Quarterly Operations Report and Appendix | January 2020 | View ASX Announcement |
| Document name | date | Link |
|---|---|---|
| Report to Shareholders and Outlook for 2020 | December 2019 | View ASX Announcement |
| Appendix 3G: Notification of issue, conversion or payment up of equity +securities | December 2019 | View ASX Announcement |
| Appendix 3Y: Change of Director’s Interest Notice | December 2019 | View ASX Announcement |
| Results of Annual General Meeting | November 2019 | View ASX Announcement |
| Company Update | November 2019 | View ASX Announcement |
| Final Directors Interest Notice | November 2019 | View ASX Announcement |
| Medibio Provides Updated Securities Trading Policy | October 2019 | View ASX Announcement |
| Medibio Successfully Completes First Pilot with Compass Group | October 2019 | View ASX Announcement |
| Medibio Notice of Annual General Meeting and Proxy Form | October 2019 | View ASX Announcement |
| Notice of Ceasing to be a Substantial Holder | October 2019 | View ASX Announcement |
| Medibio CEO to Participate on Panel at Garmin Digital Health Summit APAC | October 2019 | View ASX Announcement |
| Medibio Signs Agreement with PwC Australia for ilumen™ | October 2019 | View ASX Announcement |
| Quarterly Update and Appendix 4C 31 October 2019 | October 2019 | View ASX Announcement |
| Withdrawal of Notice of Initial Substantial Shareholding | September 2019 | View ASX Announcement |
| Becoming A Substantial Holder 2 Sept 2019 | September 2019 | View ASX Announcement |
| Change in Substantial Holding 3 Sept 2019 | September 2019 | View ASX Announcement |
| Cleansing Notice 4 September 2019 | September 2019 | View ASX Announcement |
| Change of Directors Interest 4 Sept 2019 | September 2019 | View ASX Announcement |
| Initial Directors Interest 4 Sept 2019 | September 2019 | View ASX Announcement |
| Medibio Announces Results of Review of Partly Paid Shares | September 2019 | View ASX Announcement |
| Medibio Appendix 4G and Governance Statement | September 2019 | View ASX Announcement |
| Medibio 2019 Annual Report | September 2019 | View ASX Announcement |
| Medibio Supplementary Prospectus | August 2019 | View ASX Announcement |
| Medibio Results of August 2019 AGM | August 2019 | View ASX Announcement |
| Medibio Appendix 3B 20 August 2019 | August 2019 | View ASX Announcement |
| Medibio Completes Oversubscribed Share Purchase Plan | August 2019 | View ASX Announcement |
| Medibio ASX Information for New Quoted Option Class | August 2019 | View ASX Announcement |
| Medibio Appendix 3B 29 August 2019 | August 2019 | View ASX Announcement |
| Medibio Announces New Board Members and Establishes Growth & Advocacy Advisory Board | August 2019 | View ASX Announcement |
| Medibio Announces Fourth Pilot Agreement with Compass Group | August 2019 | View ASX Announcement |
| Medibio Appendix 4E Preliminary Report | August 2019 | View ASX Announcement |
| Medibio Becoming a Substantial Holder 30 Aug 2019 | August 2019 | View ASX Announcement |
| Medibio Appendix 3B 30 Aug 2019 | August 2019 | View ASX Announcement |
| Medibio Final Directors Notice 30 Aug 2019 | August 2019 | View ASX Announcement |
| Medibio Signs Global Organisation, Compass Group PLC, for the First of Two UK-based Pilots for ilumen™ | July 2019 | View ASX Announcement |
| Medibio Requests Trading Halt in Relation to Capital Raising | July 2019 | View ASX Announcement |
| Medibio Suspension from Official Quotation | July 2019 | View ASX Announcement |
| Medibio Reinstatement to Official Quotation | July 2019 | View ASX Announcement |
| Medibio Raises $4,020,000 By Way of a Placement and Fully Underwritten SPP | July 2019 | View ASX Announcement |
| Medibio Signs Second Compass Group PLC Pilot for ilumen™ | July 2019 | View ASX Announcement |
| Medibio Notice of Extraordinary General Meeting, Explanatory Statement and Proxy Form | July 2019 | View ASX Announcement |
| Medibio Notice of Change of Interest of Substantial Holder | July 2019 | View ASX Announcement |
| Medibio Prospectus Offer of Options and Shares for SPP | July 2019 | View ASX Announcement |
| Medibio Appendix 3B | July 2019 | View ASX Announcement |
| Medibio Partners with Digital Corporate Wellness Solution Leader WellteQ | July 2019 | View ASX Announcement |
| Medibio Signs Compass Group Australia for Corporate Health Product ilumen™ | July 2019 | View ASX Announcement |
| Medibio Quarterly Operations Report and Appendix 4C | July 2019 | View ASX Announcement |
| Appendix 3B New Issue Announcement | June 2019 | View ASX Announcement |
| Joint Venture Dispute | June 2019 | View ASX Announcement |
| Change of Directors Notice | June 2019 | View ASX Announcement |
| Medibio Algorithm Validated in Study Published in Peer Reviewed Journal | June 2019 | View ASX Announcement |
| Medibio Provides Updated Investor Deck | May 2019 | View ASX Announcement |
| Medibio Results of General Meeting | May 2019 | View ASX Announcement |
| Medibio Response to ASX 4C Query | May 2019 | View ASX Announcement |
| Medibio Provides Updated Investor Deck 27 May 2019 | May 2019 | View ASX Announcement |
| Medibio Provides Notice of General Meeting | April 2019 | View ASX Announcement |
| Medibio Announces Sponsored Research Agreement with Humanitas | April 2019 | View ASX Announcement |
| Medibio Announces Revised Regulatory and Commercialisation Strategy | April 2019 | View ASX Announcement |
| Medibio Provides Quarterly Message and Appendix 4C | April 2019 | View ASX Announcement |
| Medibio Corporate Health Product ilumen™ Successfully Completes First Commercial Program | March 2019 | View ASX Announcement |
| Medibio Announces Entitlement Issue Results and Shortfall Notification | March 2019 | View ASX Announcement |
| Medibio Outsources Psychology Services in Support of Corporate Health Product ilumen™ | March 2019 | View ASX Announcement |
| Medibio Announces Completion of Entitlement Issue | March 2019 | View ASX Announcement |
| Medibio Shareholder Update & Outlook | March 2019 | View ASX Announcement |
| Medibio Provides Updated Investor Presentation | March 2019 | View ASX Announcement |
| Medibio Extension of Entitlement Offering | February 2019 | View ASX Announcement |
| Medibio Investor Presentation | February 2019 | View ASX Announcement |
| Medibio Announces Changes to Board of Directors and Appointment of Chairman | February 2019 | View ASX Announcement |
| Medibio Announces Extension to Entitlement Offer | February 2019 | View ASX Announcement |
| Medibio Correction to Extension of Entitlement Offer | February 2019 | View ASX Announcement |
| Medibio Appendix 4D Half Year Report | February 2019 | View ASX Announcement |
| Medibio Results of January 2019 General Meeting | January 2019 | View ASX Announcement |
| Medibio Cleansing Notice and Appendix 3B | January 2019 | View ASX Announcement |
| Medibio Quarterly Update & Cash Flow | January 2019 | View ASX Announcement |
| Document name | date | Link |
|---|---|---|
| Medibio Requests Trading Halt | December 2018 | View ASX Announcement |
| Medibio Converting Note & Non-Renounceable Entitlement Offer | December 2018 | View ASX Announcement |
| Medibio Section 708AA(2)(F) Cleansing Statement and Appendix 3B | December 2018 | View ASX Announcement |
| Medibio Updated Investor Presentation December 10, 2018 | December 2018 | View ASX Announcement |
| Medibio Notification of Pro-Rata Non-Renounceable Entitlement Issue | December 2018 | View ASX Announcement |
| Medibio Letter to Shareholders Entitlement Offer | December 2018 | View ASX Announcement |
| Medibio Letter to Ineligible Shareholders Entitlement Offer | December 2018 | View ASX Announcement |
| Medibio Rights Issue Offer Document | December 2018 | View ASX Announcement |
| Medibio Notice of General Meeting | December 2018 | View ASX Announcement |
| Medibio Announces Changes to the Board of Directors and Cost Reduction Plans | December 2018 | View ASX Announcement |
| Medibio Market Update | November 2018 | View ASX Announcement |
| Medibio Appoints Global Healthcare & Medical Device Leader as CEO and Managing Director | November 2018 | View ASX Announcement |
| Medibio Provides Update on FDA Process | November 2018 | View ASX Announcement |
| Medibio Provides Chairman’s Address to Shareholders | November 2018 | View ASX Announcement |
| Medibio Announces Appointment of Joint Corporate Secretary | November 2018 | View ASX Announcement |
| Medibio Releases Results of Annual General Meeting | November 2018 | View ASX Announcement |
| Medibio Signs Insurance Company AIA Australia Ltd (AIAA) For an Exclusive Pilot Program For ilumen™ | November 2018 | View ASX Announcement |
| Medibio Provides Updated Investor Deck | November 2018 | View ASX Announcement |
| Notice Received Under Section 249D of the Corporations Act | October 2018 | View ASX Announcement |
| Medibio Releases Corporate Health Product, ilumen™ | October 2018 | View ASX Announcement |
| Medibio Updates Company Presentation | October 2018 | View ASX Announcement |
| Medibio Technology Honored with Two Presentations at Mayo Clinic Convergence Neuroscience 2018 | October 2018 | View ASX Announcement |
| Medibio Receives R&D Tax Incentive Refund | October 2018 | View ASX Announcement |
| Medibio Notice of Annual General Meeting | October 2018 | View ASX Announcement |
| Medibio Signs ilumen™ Corporate Contract with a Large Australian Employer | October 2018 | View ASX Announcement |
| Medibio Quarterly & Cash Flow Report | October 2018 | View ASX Announcement |
| Medibio Clinical Study Shows Over 20% Improvement to Current Diagnostic Standard | September 2018 | View ASX Announcement |
| Medibio Hosts Call to Discuss Clinical Validation Study | September 2018 | View ASX Announcement |
| Medibio Market Update | September 2018 | View ASX Announcement |
| Medibio Releases Appendix 4G & Corporate Governance Statement | September 2018 | View ASX Announcement |
| Medibio Releases Financial Report for the Year Ended 30 June 2018 | September 2018 | View ASX Announcement |
| Medibio Announces Executive Leadership Changes | September 2018 | View ASX Announcement |
| Medibio announces change in senior management | August 2018 | View ASX Announcement |
| Medibio Submits FDA De Novo Application | July 2018 | View ASX Announcement |
| Medibio to announce fourth quarter FY18 results | July 2018 | View ASX Announcement |
| Quarterly Update and Message from CEO of Medibio Limited | July 2018 | View ASX Announcement |
| Appointment and Resignation of Company Secretary And Change of Registered Office Address | June 2018 | View Press Release PDF |
| Medibio provides updated Investor Presentation | June 2018 | View Press Release PDF |
| Medibio to Provide Corporate Health Investor Presentation | June 2018 | View Press Release PDF |
| Peer-reviewed Neurology Publication on Medibio Science | June 2018 | View ASX Announcement |
| Medibio Announces Global Launch – Corporate Mental Health For Business | May 2018 | View Press Release PDF |
| Medibio Receives CE Certification | May 2018 | View Press Release PDF |
| Medibio Corporate Health contract signed with Australia’s 3rd largest private healthcare provider | May 2018 | View Press Release PDF |
| Medibio Launches Personal Mental Health Measurement App for Apple Watch | May 2018 | View Press Release PDF |
| Medibio Announces Next Tranche of Corporate Health Contracts | May 2018 | View Press Release PDF |
| Medibio Corporate Health Signs Global Contract with Jacobs Engineering | May 2018 | View Press Release PDF |
| Medibio finalizes acquisition of Vital Conversations | April 2018 | View Press Release PDF |
| Medibio Announces Scientific Advisory Board | April 2018 | View Press Release PDF |
| Medibio to announce third Quarter FY18 update and cashflow | April 2018 | View ASX Announcement |
| Quarterly ASX Update and Cashflows | April 2018 | View ASX Announcement |
| Peter Carlisle Appointed as Director | January 2018 | View Press Release PDF |
| Medibio Investor Conference Call Announcement | January 2018 | Australia – 1st February U.S. – January 31st |
| Document name | date | Link |
|---|---|---|
| U.S. Department of Veterans Affairs White River Junction Medical Center Joins Medibio Depression Diagnostic Confirmatory Study to Support FDA Clearance | December 2017 | View ASX Announcement |
| Mayo Clinic to begin Prospective Clinical Study with Medibio Technology for Expanded Market Opportunities | December 2017 | View ASX Announcement |
| Medibio Annual General Meeting Materials | November 2017 | View ASX Announcement Watch Videos |
| Medibio Enters Into an Agreement with Otsuka Pharmaceutical Development & Commercialization, Inc. | October 2017 | View ASX Announcement |
| Medibio’s Depression Diagnostic Ready for FDA Confirmatory Study. (Aug 2 2017) | August 2017 | View ASX Announcement |
| Medibio Initiates Enrollment for Its Depression Diagnostic Confirmatory Study to Support FDA Clearance (Aug 21 2017) | August 2017 | View ASX Announcement |
| The Honourable Patrick Kennedy Appointed to Medibio Board of Directors (2 Jul 2017) | July 2017 | View ASX Announcement |
| Adam Darkins, Telehealth icon appointed to Medibio board (19 Jul 2017). | July 2017 | View ASX Announcement |
| Michael Phelps, World Champion Athlete and Mental Health Advocate, Appointed to Medibio Board of Directors (5 Jun 2017) | June 2017 | View ASX Announcement |
| Medibio Limited Begins Trading on OTCQB Under Ticker Symbol MDBIF (5 Jun 2017) | June 2017 | View ASX Announcement |
| Medibio Investor Deck Update (5 Jun 2017) | June 2017 | View ASX Announcement |
| Independent researchers present first data validating Medibio’s technology at the prestigious “Sleep 2017” (8 Jun 2017) | June 2017 | View ASX Announcement |
| Scientific breakthrough on objective diagnosis of PTSD (27 Jun 2017) | June 2017 | View ASX Announcement |
| Medibio signs strategic joint Development Agreement with Mayo Clinic. | May 2017 | View ASX Announcement |
| Medibio appoints experienced US based med-tech CFO (21 Apr 2017) | April 2017 | View ASX Announcement |
| Change of Director’s Interest Notice (20 Apr 2017) | April 2017 | View ASX Announcement |
| MEB enters fully funded Paediatric mental illness diagnostic (10 Apr 2017) | April 2017 | View ASX Announcement |
| Conversion of Options to Partly Paid shares (5 Apr 2017) | April 2017 | View ASX Announcement |
| Change of Director’s Interest Notice (5 Apr 2017) | April 2017 | View ASX Announcement |
| Investor Presentation Deck (20 Mar 2017) | March 2017 | View ASX Announcement |
| Appointment of Non Executive Director & Advisory Board Chang (1 Feb 2017) | February 2017 | View ASX Announcement |
| Medibio Appoints US and med-tech veteran as CEO and Managing Director (16 Feb 2017) | February 2017 | View ASX Announcement |
| Partnership with leading US University on Post Traumatic Stress Disorder (25 Jan 2017) | January 2017 | View ASX Announcement |
| Early Repayment of Convertible Note (30 Jan 2017) | January 2017 | View ASX Announcement |
| Quarterly Update – Q4 2016 (31 Jan 2017) | January 2017 | View ASX Announcement |
| Document name | date | Link |
|---|---|---|
| APP 3B (5 Dec 2016) | December 2016 | View ASX Announcement |
| Medibio’s Depression Diagnostic demonstrated excellent performance in the pilot phase of its US Validation Study (21 Dec 2016) | December 2016 | View ASX Announcement |
| Medibio’s Depression Diagnostic demonstrates excellent performance in the pilot phase of its US Validation Study (21 Dec 2016) | December 2016 | View ASX Announcement |
| App 3B (3 Nov 2016) | November 2016 | View ASX Announcement |
| University of Ottawa Depression Study improves accuracy rate to an outstanding 86% in a far larger sample. (Nov 16) | November 2016 | View ASX Announcement |
| Capital raising of $13.5 million to accelerate growth (Nov 16) | November 2016 | View ASX Announcement |
| Medibio Limited announces that Dr James Campbell has resigned as a Non-Executive Director of Medibio | November 2016 | View ASX Announcement |
| Medibio AGM Presentation (Nov 29) | November 2016 | View ASX Announcement |
| App 3B (7 Oct 2016) | October 2016 | View ASX Announcement |
| Funding Update (10 Oct 16) | October 2016 | View ASX Announcement |
| MEB Annual 2016 (10 Oct 2016) | October 2016 | View ASX Announcement |
| Partners with HBF and Vital Conversation (11 Oct 2016) | October 2016 | View ASX Announcement |
| MEB R & D Tax Incentive Refund | October 2016 | View ASX Announcement |
| Notice of Annual General Meeting (28 Oct 2016) | October 2016 | View ASX Announcement |
| Medibio Shareholder Newsletter (28 Oct 2016) | October 2016 | View ASX Announcement |
| App 3B (28 Oct 2016) | October 2016 | View ASX Announcement |
| Quarterly report (31 Oct 2016) | October 2016 | View ASX Announcement |
| Quarterly Cash Flow Report (30 Oct 2016) | October 2016 | View ASX Announcement |
| MEB and Monash establish groundbreaking partnership on innovation for sleep and mental health solution (September 2016) | September 2016 | View ASX Announcement |
| Director’s Resignation (30 Sep 2016) | September 2016 | View ASX Announcement |
| Trading Halt Request (5 Aug 2016) | August 2016 | View ASX Announcement |
| Depression Validation Results (August 2016) | August 2016 | View ASX Announcement |
| BMC Collaboration (17 Aug 2016) | August 2016 | View ASX Announcement |
| Investor Presentation (23 Aug 2016) | August 2016 | View ASX Announcement |
| Preliminary Final Report (31 Aug 2016) | August 2016 | View ASX Announcement |
| Quarterly Report (31 Jul 2016) | July 2016 | View ASX Announcement |
| Medibio’s Advanced Analytics Cloud Solution Breaks (24 June 2016) | June 2016 | View ASX Announcement |
| US Investor Presentation (28 June 2016) | June 2016 | View ASX Announcement |
| App 3B (30 June 2016) | June 2016 | View ASX Announcement |
| First Commercial Pilot (30 May 2016) | May 2016 | View ASX Announcement |
| Investor Presentation April 2016 (4 April 2016) | April 2016 | View ASX Announcement |
| Medibio Acquires Key IP (19 April 2016) | April 2016 | View ASX Announcement |
| Shareholder Newsletter Issue 3 – (21 April 2016) | April 2016 | View ASX Announcement |
| 708 Disclosure (29 April 2016) | April 2016 | View ASX Announcement |
| Appendix 3B New issue announcement (29 April 2016) | April 2016 | View ASX Announcement |
| Quarterly Report – March 2016 (30 April 2016) | April 2016 | View ASX Announcement |
| Apple Watch and Fitbit intergration (8 March 2016) | March 2016 | View ASX Announcement |
| Four leading US Institutions provide Medibio 10000 data sets (14 March 2016) | March 2016 | View ASX Announcement |
| BioMelbourne Conference on Wireless and Wearable Technology (17 March 2016) | March 2016 | View ASX Announcement |
| Partnership to evaluate wearables (8 Feb 2016) | February 2016 | View ASX Announcement |
| First Wellness Channel Partner commercial pilot (16 Feb 2016) | February 2016 | View ASX Announcement |
| MEB Half Yearly Report and Accounts to 31 December 2015 (28 Feb 2016) | February 2016 | View ASX Announcement |
| MEB Receipt of R & D Tax Incentive Refund (14 Jan 2016) | January 2016 | View ASX Announcement |
| MEB ASX Rlease Re-Frank Prendergast(27 Jan 2016) | January 2016 | View ASX Announcement |
| MEB Initial Directors Interest (27 Jan 2016) | January 2016 | View ASX Announcement |
| MEB Dec Quarterly Report (31 Jan 2016) | January 2016 | View ASX Announcement |
| MEB Agreement with Wellnovation (31 Jan 2015) | January 2016 | View ASX Announcement |
| MEB Appendix 3B Amendment and re-lodgement (31 Jan 2016) | January 2016 | View ASX Announcement |
| Document name | date | Link |
|---|---|---|
| MEB and WellNovation MOU takes stress diagnostic to Saudi Arabia and Gulf Cooperation Council | December 2015 | View ASX Announcement |
| MEB Quarterly Report for the period ending (30 Sep 2015) | November 2015 | View ASX Announcement |
| MEB’s Signs First Multinational Client (6 Nov 2015) | November 2015 | View ASX Announcement |
| MEB Foster Research Report (10 Nov 2015) | November 2015 | View ASX Announcement |
| MEB ASX Investor Series Presentation (17 Nov 2015) | November 2015 | View ASX Announcement |
| MEB Final JHU Release-IRB (ASX Release) (24 Nov 2015) | November 2015 | View ASX Announcement |
| MEB Corporate Wellness Partner Program Commences (26 Nov 2015) | November 2015 | View ASX Announcement |
| MEB Key to Disclosures Corporate Governance Council Principles and Recommendations | October 2015 | View ASX Announcement |
| MEB collaborates with University of Ottawa on research (12 Oct 2015) | October 2015 | View ASX Announcement |
| MEB Annual Report 2015 (28 Oct 2015) | October 2015 | View ASX Announcement |
| MEB Notice of Annual General Meeting (30 Oct 2015) | October 2015 | View ASX Announcement |
| MEB Capital raising of $3.1 million to accelerate growth (2 September 2015) | September 2015 | View ASX Announcement |
| MEB launches Corporate Wellness Partner Program for its Corporate Stress Product (25 September 2015) | September 2015 | View ASX Announcement |
| MEB June 2015 Quarter Operations Report (4 Aug 2015) | August 2015 | View ASX Announcement |
| MEB US Broker Report (17 Aug 2015) | August 2015 | View ASX Announcement |
| MEB US Update (17 Aug 2015) | August 2015 | View ASX Announcement |
| MEB Completes Development of Corporate Stress Product (21 Aug 2015) | August 2015 | View ASX Announcement |
| MEB First Commercial Deal (27 August 2015) | August 2015 | View ASX Announcement |
| MEB Investor Presentation (August 2015) | August 2015 | View ASX Announcement |
| MEB Stress Patent (2 July 2015) | July 2015 | View ASX Announcement |
| MEB Medical Patent (15 July 2015) | July 2015 | View ASX Announcement |
| MEB Investor Presentation (July 2015) | July 2015 | View ASX Announcement |
| Medibio Ltd processes first participant in UNSW depression test validation study (11 May 2015) | May 2015 | View ASX Announcement |
| March Quarterly Activities Report (13 May 2015) | May 2015 | View ASX Announcement |
| MEB Preventice MOU Release (28 May 2015) | May 2015 | View ASX Announcement |
| Medibio Press Article (May 2015) | May 2015 | View ASX Announcement |
| Medibio Investor Presentation (April 2015) | April 2015 | View ASX Announcement |
| Completion of Restructure (2 April 2015) | April 2015 | View ASX Announcement |
| Distinguished Clinician Dr Frank Prendergast joins MEB (12 April 2015) | April 2015 | View ASX Announcement |
| U.S. Patent (21 April 2015) | April 2015 | View ASX Announcement |
| Investor Presentation April 2016 (4 April 2016) | April 2015 | View ASX Announcement |
| Medibio Acquires Key IP (19 April 2016) | April 2015 | View ASX Announcement |
| Shareholder Newsletter Issue 3 – (21 April 2016) | April 2015 | View ASX Announcement |
| 708 Disclosure (29 April 2016) | April 2015 | View ASX Announcement |
| Appendix 3B New issue announcement (29 April 2016) | April 2015 | View ASX Announcement |
| Quarterly Report – March 2016 (30 April 2016) | April 2015 | View ASX Announcement |
| Broker Research (22 April 2015) | April 2015 | View ASX Announcement |
| Medibo Investor Newsletter | March 2015 | View ASX Announcement |
| Results of General Meeting (6 March 2015) | March 2015 | View ASX Announcement |
| General Meeting Presentation (6 March 2015) | March 2015 | View ASX Announcement |
| U.S. Depression market size (6 Feb 2015) | February 2015 | View ASX Announcement |
| Medibio Limited Health Stage 1 Program | February 2015 | View ASX Announcement |
| Medibio Presentation Jan 2015(ASX Release) | January 2015 | View ASX Announcement |
| Market Update restructure (Final) | January 2015 | View ASX Announcement |
| Document name | date | Link |
|---|---|---|
| MEB (JHU Release) Lodgement Version | December 2014 | View ASX Announcement |
| NAMSA US Trials | December 2014 | View ASX Announcement |
| BPO Share Issue Cleansing Statement | November 2014 | View ASX Announcement |
| BPO Trading Halt Request correction | November 2014 | View ASX Announcement |
| BPO ASX Release Name Change | November 2014 | View ASX Announcement |
| BPO ASX Release AGM Results | November 2014 | View ASX Announcement |
| BPO Appendix 3B B Kay Taurus C Note Share Issue revised | November 2014 | View ASX Announcement |
| BPO ASX Release MJP Appointment approved for release | November 2014 | View ASX Announcement |
| BPO ASX Release BDI Study | November 2014 | View ASX Announcement |
| BPO Baillieu Holst Research | October 2014 | View ASX Announcement |
| Stephen Pearce, Fortescue Metals CFO, joins BPO as Advisor | July 2014 | View ASX Announcement |
| Final Director’s Interest Notice | July 2014 | View ASX Announcement |
| Change in Substantial Holding | July 2014 | View ASX Announcement |
| Initial Director’s Interest Notice | July 2014 | View ASX Announcement |
| Board Appointment | July 2014 | View ASX Announcement |
| Change of Director’s Interest Notice | June 2014 | View ASX Announcement |
| BPO Responds to Explosive Demand for E-Health Consumer Prod | June 2014 | View ASX Announcement |
| Change in substantial Holding | June 2014 | View ASX Announcement |
| Change of Director’s Interest Notice | June 2014 | View ASX Announcement |
| Appendix 3B | May 2014 | View ASX Announcement |
| BioProspect Letter to Shareholders | May 2014 | View ASX Announcement |
| Frontier Oil Corporation Update | May 2014 | View ASX Announcement |
| Appendix 3Z B Cooper | May 2014 | View ASX Announcement |
| Appendix 4C March 2014 | April 2014 | View ASX Announcement |
| Appendix 3X V Fayad | April 2014 | View ASX Announcement |
| Appendix 3X C Solitario | April 2014 | View ASX Announcement |
| BioProspect Board Changes & Executive Appointments | April 2014 | View ASX Announcement |
| BioProspect Acquires Diagnostic Tool for Mental Illness | April 2014 | View ASX Announcement |
| Successful Completion of Technical Due Diligence | March 2014 | View ASX Announcement |
| Appendix 4D | March 2014 | View ASX Announcement |
| Frontier Oil Corporation Update | February 2014 | View ASX Announcement |
| Results of General Meeting | February 2014 | View ASX Announcement |
| Invatec Heartlink Transaction Update | February 2014 | View ASX Announcement |
| Appendix 3B | January 2014 | View ASX Announcement |
| Issue of Convertible Notes | January 2014 | View ASX Announcement |
| Change of Interest of Substantial Holder | January 2014 | View ASX Announcement |
| Appendix 4C | January 2014 | View ASX Announcement |
| Notice of Meeting | January 2014 | View ASX Announcement |
| Document name | date | Link |
|---|---|---|
| Expiry of Options | December 2013 | View ASX Announcement |
| Investor Presentation Invatec | December 2013 | View ASX Announcement |
| Expiry of Options | December 2013 | View ASX Announcement |
| Cleansing Statement | December 2013 | View ASX Announcement |
| Appendix 3B | December 2013 | View ASX Announcement |
| Options to acquire Depression Diagnostic Project | December 2013 | View ASX Announcement |